Kalofonos Isabel, Chief Commercial Officer at Crinetics Pharmaceuticals ($CRNX), made one open market sale of common shares in the last 365 days, totaling $137,500. Her most recent sale occurred on January 5, 2026. This places her 9,119th among 11,678 insiders by sales value, well below the average of $8.6 million across about 6.4 transactions per insider. She reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 23, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | A | Common Stock | 34000 | $0.00 | 34,834.0000 | 94,548,000 | 4076.74% | 0.04% |
| Feb. 23, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 94,548,000 | 9999.99% | 0.06% |
| Jan. 5, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | M | Common Stock | 2500 | $40.59 | 3,334.0000 | 94,548,000 | 299.76% | 0.00% |
| Jan. 5, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | S | Common Stock | 2500 | $55.00 | 834.0000 | 94,548,000 | 74.99% | 0.00% |
| Jan. 5, 2026 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | M | Stock Option (Right to Buy) | 2500 | $0.00 | 97,500.0000 | 94,548,000 | 2.50% | 0.00% |
| Jan. 10, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Kalofonos Isabel | Chief Commercial Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 92,926,000 | 9999.99% | 0.11% |